一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Tafolecimab；Sintilimab，当前状态为招募中。登记地点显示中国重庆有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tafolecimab；Sintilimab · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至80 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Daping Hospital Third Military Medical University · 重庆
公开的入选条件
- * Signed the written informed consent form and voluntarily participate in the study.
- * Pathohistologically confirmed colon adenocarcinoma with cT3c stage or above.
- * Aged 18 to 80 years, regardless of gender.
- * The lower edge of the tumor is more than 10 cm from the anus.
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- * Sufficient bone marrow, liver, kidney and coagulation functions assessed by laboratory tests (in accordance with the local laboratory reference range).
- * No previous anti-tumor treatment for the current colon cancer (including radiotherapy, chemotherapy, surgery, etc.).
- * No pregnancy or lactation for female patients; male patients agree to take effective contraceptive measures during the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07840677；登记信息更新于 2026-09-25。